Phase 2 trial of DS-1062a in pretreated advanced NSCLC with genomic alterations posts no results

This was a Phase 2 interventional clinical trial investigating the antibody-drug conjugate DS-1062a. The study enrolled 137 participants with advanced or metastatic non-small cell lung cancer (NSCLC) harboring actionable genomic alterations. All participants had been previously treated with at least 1 platinum-containing therapy and 1 or more lines of targeted therapy. The intervention was DS-1062a administered at a dose of 6.0 mg/kg. The primary outcome was the percentage of participants achieving an objective response rate (ORR) as assessed by blinded independent central review (BICR). No comparator arm was reported. No efficacy results, including the primary ORR endpoint, were provided in the input data. Similarly, no safety or tolerability data—such as rates of adverse events, serious adverse events, or treatment discontinuations—were reported. The study's follow-up duration and specific secondary outcomes were also not detailed. Key limitations include the absence of reported results, which precludes any assessment of efficacy or safety. The trial setting and specific actionable alterations within the population were not described. The study was sponsored by Daiichi Sankyo, the developer of DS-1062a. Given the complete lack of reported outcomes, no conclusions can be drawn regarding the drug's activity, safety profile, or potential role in this pretreated patient population. Clinical interpretation must await the publication of peer-reviewed results.

Researchers conducted a Phase 2 clinical trial to learn about a drug called DS-1062a. They studied it in 137 people with advanced or metastatic non-small cell lung cancer (NSCLC) who had specific genetic changes in their cancer. All participants had already received at least one platinum-based chemotherapy and one or more targeted therapies for their cancer. The main goal was to see how well the drug worked, how safe it was, and how it was processed by the body.

The trial was designed to measure the percentage of participants whose tumors shrank significantly, which is called the objective response rate. This measurement was planned to be reviewed by an independent central team to avoid bias. The study did not compare DS-1062a to another treatment or a placebo.

No results from this specific trial are available in the provided information. This means we do not yet know if the drug was effective, how patients tolerated it, or what side effects occurred. The trial was sponsored by the drug's developer, Daiichi Sankyo.

It is important to remember that this was a Phase 2 trial, which is a mid-stage study designed to gather initial evidence about a drug's effectiveness and safety. These studies are not large enough to provide definitive proof. Readers should understand that this report only describes a study that was conducted, not its outcomes. The findings, when they become available, will need to be confirmed in larger Phase 3 trials before the drug could be considered for approval.